AQR Capital Management LLC Purchases 73,122 Shares of QIAGEN N.V. $QGEN

AQR Capital Management LLC increased its position in QIAGEN N.V. (NYSE:QGEN) by 69.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 178,425 shares of the company’s stock after purchasing an additional 73,122 shares during the period. AQR Capital Management LLC owned approximately 0.08% of QIAGEN worth $7,164,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wealth Enhancement Advisory Services LLC bought a new position in shares of QIAGEN in the fourth quarter valued at $202,000. GAMMA Investing LLC lifted its position in QIAGEN by 93.9% in the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock valued at $118,000 after acquiring an additional 1,425 shares in the last quarter. Cetera Investment Advisers boosted its stake in QIAGEN by 23.2% during the 1st quarter. Cetera Investment Advisers now owns 13,917 shares of the company’s stock valued at $551,000 after purchasing an additional 2,620 shares during the last quarter. Avantax Advisory Services Inc. increased its holdings in QIAGEN by 30.2% during the 1st quarter. Avantax Advisory Services Inc. now owns 9,869 shares of the company’s stock worth $396,000 after purchasing an additional 2,290 shares in the last quarter. Finally, Federated Hermes Inc. purchased a new stake in shares of QIAGEN in the first quarter worth approximately $150,000. Institutional investors own 70.00% of the company’s stock.

QIAGEN Price Performance

Shares of QIAGEN stock opened at $46.06 on Friday. The firm has a market capitalization of $10.24 billion, a PE ratio of 27.21, a price-to-earnings-growth ratio of 2.43 and a beta of 0.64. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25. QIAGEN N.V. has a 12 month low of $37.63 and a 12 month high of $51.88. The business’s 50-day moving average price is $48.53 and its 200-day moving average price is $44.55.

QIAGEN (NYSE:QGEN) last released its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.60. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The company had revenue of $533.54 million during the quarter, compared to the consensus estimate of $523.97 million. During the same quarter in the previous year, the company posted $0.55 EPS. QIAGEN’s quarterly revenue was up 7.7% compared to the same quarter last year. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Sell-side analysts forecast that QIAGEN N.V. will post 2.26 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on QGEN. UBS Group lifted their price objective on shares of QIAGEN from $48.00 to $50.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Cowen reiterated a “hold” rating on shares of QIAGEN in a research note on Thursday, August 7th. Bank of America lifted their price target on QIAGEN from $50.00 to $53.00 and gave the company a “buy” rating in a research report on Thursday, June 26th. Wall Street Zen cut QIAGEN from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 11th. Finally, Barclays started coverage on QIAGEN in a research report on Tuesday, June 24th. They issued an “overweight” rating and a $55.00 price objective on the stock. Three analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, QIAGEN currently has an average rating of “Hold” and an average target price of $49.69.

QIAGEN Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.